Pharmaceutical

OCT-461201 by Oxford Cannabinoid Technologies for Neuropathic Pain (Neuralgia): Likelihood of Approval

OCT-461201 is under clinical development by Oxford Cannabinoid Technologies and currently in Phase I for Neuropathic Pain (Neuralgia).

Jun 18, 2024 - 04:00
OCT-461201 is under clinical development by Oxford Cannabinoid Technologies and currently in Phase I for Neuropathic Pain (Neuralgia).
Read the original article

Tags:

Previous Article

OCT-461201 by Oxford Cannabinoid Technologies for Visceral Pain: Likelihood of A...

Next Article

MEDI-0618 by AstraZeneca for Migraine: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Unresolved clawback issues obstruct Greece’s potential pharmaceutical framework agreement

Unresolved clawback issues obstruct Greece’s potential ...

Oct 20, 2024

STAT+: How a key Senate committee is planning to regulate pharmacy benefit managers

STAT+: How a key Senate committee is planning to regula...

Jul 14, 2023

CHMP recommends full marketing approval for Gilead Sciences’ Hepcludex

CHMP recommends full marketing approval for Gilead Scie...

May 6, 2023